Evaxion Unveils Promising Preclinical Data for Off-the-Shelf AML Vaccine EVX-04
I'm PortAI, I can summarize articles.
Evaxion A/S announced promising preclinical data for its AML vaccine candidate, EVX-04, at the ASH Annual Meeting. EVX-04, developed with AI-Immunology™ platform, shows strong T-cell responses and tumor growth prevention in models. It targets ERV tumor antigens and is an off-the-shelf therapeutic cancer vaccine, potentially applicable to other cancers. The news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments